Articles

Current advances in cytogenomics – Implementation of Optical Genome Mapping into diagnostic workflows for haematological neoplasms: A Belgian Cytogenomic Group for Haemato-Oncology (BCG-HO) position statement

BJH - volume 15, issue 6, october 2024

K. Rack PhD, N. Van Roy PhD, P. Chiarappa PhD, J. Luciani PhD, C. Dressen PhD, S. Horion MSc, J. de Bie MD, PhD, G. Ameye MSc, J. Vanhevel PhD, L. Michaux MD, PhD, S. Beckers PhD, L. Rooms PhD, P. Heimann MD, PhD, T. Sticca PhD, M. Jamar MD, PhD, S. Toffoli PhD, MSc, C. Menten PhD, C. Lété PhD, S. Franke PhD, B. Dewaele PhD

SUMMARY

Genomic abnormalities play an increasingly important role in prognostication and classification of haematological malignancies (HM), as evidenced by their continual integration into updated classification and risk assessment models. Optical Genome Mapping (OGM) is a relatively new high-resolution technology that offers novel opportunities to assess chromosome abnormalities, increasing the detection yield of clinically relevant abnormalities and allowing rationalisation of diagnostic pathways by abrogating the need for multiple complementary tests. Furthermore, it could streamline laboratory’s technical pipelines, avoiding the need for multiple disease specific workflows. Given these findings, OGM is currently being implemented into the diagnostic workflow, as a first line test, by numerous laboratories worldwide and is being validated with view to implementation in many more, including Belgium. Here we propose recommendations for implementation of OGM testing in the routine diagnostic workup of HM.

(BELG J HEMATOL 2024;15(6):233–7)

Read more

P41 A 54-year-old woman with a myeloid neoplasm associated with eosinophilia and t(5;12) (q33;p13)/PDGRFB rearrangement: case report and mini-review of the literature

BJH - volume 8, issue Abstract Book BHS, february 2017

Q. Delefortrie , F. Lambert MD, G. Bulliard , M. Jurdan , S. Toffoli PhD, MSc, D. Sartenaer , S. De Prophetis , D. Pranger MD, A. Kornreich MD, P. Mineur MD

Read more